ImmuneID

ImmuneID, Inc. was founded at the end of 2020 as a precision immunology company leveraging its whole-genome, high-throughput platform to comprehensively understand individual immune responses. We employ large-scale parallel, multiplexed, and unbiased systems to develop therapies targeting autoimmune diseases, severe allergies, cancer, and infectious diseases. ImmuneID's advanced platform utilizes next-generation sequencing, robotic automation, and artificial intelligence to provide insights applicable to the development of precision immunology treatments.